GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003166722 | Liver | HCC | response to nutrient levels | 276/7958 | 474/18723 | 2.30e-12 | 1.08e-10 | 276 |
GO:019873821 | Liver | HCC | cell-cell signaling by wnt | 247/7958 | 446/18723 | 2.11e-08 | 4.96e-07 | 247 |
GO:004206022 | Liver | HCC | wound healing | 219/7958 | 422/18723 | 5.34e-05 | 5.04e-04 | 219 |
GO:009730522 | Liver | HCC | response to alcohol | 138/7958 | 253/18723 | 6.91e-05 | 6.26e-04 | 138 |
GO:004851121 | Liver | HCC | rhythmic process | 156/7958 | 298/18723 | 3.54e-04 | 2.46e-03 | 156 |
GO:001072011 | Liver | HCC | positive regulation of cell development | 155/7958 | 298/18723 | 5.39e-04 | 3.48e-03 | 155 |
GO:003249611 | Liver | HCC | response to lipopolysaccharide | 174/7958 | 343/18723 | 1.19e-03 | 6.62e-03 | 174 |
GO:000223711 | Liver | HCC | response to molecule of bacterial origin | 181/7958 | 363/18723 | 2.58e-03 | 1.24e-02 | 181 |
GO:19049501 | Liver | HCC | negative regulation of establishment of protein localization | 72/7958 | 131/18723 | 2.65e-03 | 1.27e-02 | 72 |
GO:00507674 | Liver | HCC | regulation of neurogenesis | 181/7958 | 364/18723 | 3.00e-03 | 1.40e-02 | 181 |
GO:00093146 | Liver | HCC | response to radiation | 223/7958 | 456/18723 | 3.08e-03 | 1.43e-02 | 223 |
GO:00507693 | Liver | HCC | positive regulation of neurogenesis | 116/7958 | 225/18723 | 3.67e-03 | 1.63e-02 | 116 |
GO:00025262 | Liver | HCC | acute inflammatory response | 62/7958 | 112/18723 | 4.06e-03 | 1.77e-02 | 62 |
GO:00512241 | Liver | HCC | negative regulation of protein transport | 69/7958 | 127/18723 | 4.67e-03 | 2.01e-02 | 69 |
GO:003559212 | Liver | HCC | establishment of protein localization to extracellular region | 176/7958 | 360/18723 | 7.96e-03 | 3.15e-02 | 176 |
GO:00432791 | Liver | HCC | response to alkaloid | 62/7958 | 115/18723 | 8.79e-03 | 3.42e-02 | 62 |
GO:000930612 | Liver | HCC | protein secretion | 175/7958 | 359/18723 | 9.32e-03 | 3.57e-02 | 175 |
GO:00454712 | Liver | HCC | response to ethanol | 72/7958 | 137/18723 | 1.10e-02 | 4.07e-02 | 72 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
OPRM1 | SNV | Missense_Mutation | | c.1183N>C | p.Val395Leu | p.V395L | P35372 | protein_coding | deleterious(0.05) | probably_damaging(0.938) | TCGA-AR-A1AH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | | PD |
OPRM1 | SNV | Missense_Mutation | | c.1121N>T | p.Thr374Ile | p.T374I | P35372 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
OPRM1 | SNV | Missense_Mutation | | c.1094N>G | p.Glu365Gly | p.E365G | P35372 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-BH-A18Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
OPRM1 | SNV | Missense_Mutation | | c.1397N>C | p.Arg466Thr | p.R466T | P35372 | protein_coding | tolerated(0.1) | probably_damaging(0.962) | TCGA-E2-A1IH-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | aromasin | SD |
OPRM1 | deletion | Frame_Shift_Del | | c.250_256delCACAGCG | p.His84ValfsTer45 | p.H84Vfs*45 | P35372 | protein_coding | | | TCGA-A8-A09W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
OPRM1 | insertion | Frame_Shift_Ins | novel | c.496_497insCAAATAAT | p.Ile166ThrfsTer25 | p.I166Tfs*25 | P35372 | protein_coding | | | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
OPRM1 | SNV | Missense_Mutation | novel | c.590C>T | p.Ala197Val | p.A197V | P35372 | protein_coding | tolerated(0.58) | probably_damaging(0.992) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
OPRM1 | SNV | Missense_Mutation | | c.1328N>T | p.Arg443Ile | p.R443I | P35372 | protein_coding | deleterious(0) | probably_damaging(0.967) | TCGA-EK-A3GK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
OPRM1 | SNV | Missense_Mutation | rs199560373 | c.517G>A | p.Val173Met | p.V173M | P35372 | protein_coding | deleterious(0.01) | probably_damaging(0.982) | TCGA-ZJ-AAXF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
OPRM1 | SNV | Missense_Mutation | novel | c.28N>A | p.Glu10Lys | p.E10K | P35372 | protein_coding | | benign(0.015) | TCGA-ZJ-AAXJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4988 | OPRM1 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, KINASE | | MARAVIROC | MARAVIROC | |
4988 | OPRM1 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, KINASE | agonist | 363894132 | | |
4988 | OPRM1 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, KINASE | | benzodiazepine derivatives | | |
4988 | OPRM1 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, KINASE | agonist | 178103660 | HYDROCODONE | |
4988 | OPRM1 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, KINASE | agonist | 135650245 | ETONITAZENE | |
4988 | OPRM1 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, KINASE | antagonist | 252827527 | | |
4988 | OPRM1 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, KINASE | antagonist | 135650688 | NALTRIBEN | |
4988 | OPRM1 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, KINASE | | cannabinoids | NABIXIMOLS | 11840318,31246565 |
4988 | OPRM1 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, KINASE | antagonist | 135650021 | | |
4988 | OPRM1 | G PROTEIN COUPLED RECEPTOR, DRUGGABLE GENOME, KINASE | | BUTORPHANOL | BUTORPHANOL | |